

To: [REDACTED] [REDACTED] [REDACTED]@rivm.nl]
From: [REDACTED] [REDACTED]
Sent: Sat 12/12/2020 6:12:51 PM
Subject: FW: Invitation to review for Journal of Virological Methods
Received: Sat 12/12/2020 6:12:51 PM

lets voor jou?

-----Original Message-----

From: [REDACTED] [REDACTED]@editorialmanager.com <[REDACTED] [REDACTED]@editorialmanager.com> On Behalf Of
Journal of Virological Methods
Sent: zaterdag 12 december 2020 04:50
To: [REDACTED] [REDACTED] [REDACTED]@rivm.nl>
Subject: Invitation to review for Journal of Virological Methods

Manuscript Number: VIRMET-D-20-00369
Multiplexed, Microscale, Microarray-based Serological Assay for Antibodies Against All Human-Relevant Coronaviruses

Dear Dr. [REDACTED] [REDACTED]

Dr. [REDACTED] [REDACTED] and colleagues from InDevR Inc. Colorado, USA have submitted the above manuscript for possible publication in the J. Virological Methods. The study reports the development and testing of the VaxArray for antibody detection to a variety of CoV spike proteins to facilitate COVID-19 candidate vaccine trials. The Abstract is appended below.

We would like to seek your critique of the work.

If you are able to review this paper, please click this link:

[REDACTED] [REDACTED]

If you have a conflict of interest or do not wish to review this paper, please click this link:

[REDACTED] [REDACTED]

We would appreciate your suggestions for alternate reviewers.

If, for any reason, the above links do not work, please log in as a reviewer at [REDACTED] [REDACTED]

To help with timely response to authors, could we request your review within 30 days of accepting this invitation?

Your kind consideration and early response are much appreciated to help with independent, volunteer, peer-review of the submitted work.

Thank you.

With best wishes,

[REDACTED] [REDACTED]

J. Virological Methods.

<<https://www.sciencedirect.com/journal/journal-of-virological-methods>>

Abstract:

Rapid, sensitive, and precise multiplexed assays for serological analysis during candidate COVID-19 vaccine development would streamline clinical trials. The VaxArray Coronavirus (CoV) SeroAssay quantifies IgG antibody binding to 9 pandemic, potentially pandemic, and endemic human CoV spike antigens in 2 hours with automated results analysis. IgG antibodies in serum bind to the CoV spike protein capture antigens printed in a microarray format and are labeled with a fluorescent anti-species IgG secondary label. The assay demonstrated excellent lower limits of quantification ranging from 0.3 – 2.0 ng/mL and linear dynamic ranges of 76 to 911-fold. Average precision of 11% CV and accuracy (% recovery) of 92.5% over all capture antigens were achieved over 216 replicates representing 3 days and 3 microarray lots. Clinical performance on 263 human serum samples (132 SARS-CoV-2 negatives and 131 positives based on donor-matched RT-PCR and/or date of collection) produced 98.5% PPA (sensitivity) and 100% NPA (specificity).

Please also note that authors have been invited to convert their supplementary material into a Data in Brief article (a data description article). You may notice this change alongside the revised manuscript. You do not need to review this but may need to look at the files in order to confirm that any supporting information you requested is present there.

Please also note that authors have been invited to convert methods-related supplementary material into a MethodsX article (a detailed description of their methods). You may notice this change alongside the revised manuscript. You do not need to review this but may need to look at the files in order to confirm that any supporting information you requested is present there.

Volgende pagina verwijderd i.v.m. buiten verzoek